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The in vitro susceptibilities of a worldwide collection of 350 Cryptococcus gattii isolates to seven antifungal
drugs, including the new triazole isavuconazole, were tested. With amplified fragment length polymorphism
(AFLP) fingerprinting, human, veterinary, and environmental C. gattii isolates were subdivided into seven
AFLP genotypes, including the interspecies hybrids AFLP8 and AFLP9. The majority of clinical isolates (n 
215) comprised genotypes AFLP4 (n 76) and AFLP6 (n 103). The clinical AFLP6 isolates had significantly
higher geometric mean MICs for flucytosine and fluconazole than the clinical AFLP4 isolates. Of the seven
antifungal compounds examined in this study, isavuconazole had the lowest MIC90 (0.125 g/ml) for all C.
gattii isolates, followed by a 1 log2 dilution step increase (MIC90, 0.25 g/ml) for itraconazole, voriconazole, and
posaconazole. Amphotericin B had an acceptable MIC90 of 0.5 g/ml, but fluconazole and flucytosine had
relatively high MIC90s of 8 g/ml.
The basidiomycetous yeast Cryptococcus gattii is responsible
for life-threatening invasive disease in apparently healthy hu-
mans and animals (7, 19). A typical C. gattii infection is ac-
quired through the respiratory tract, from which it can further
disseminate to the central nervous system, resulting in fatal
meningitis (7, 19, 32). Cryptococcosis caused by the primary
pathogenic yeast C. gattii was, until a decade ago, a rarely
encountered infection outside tropical and subtropical regions
(17, 26, 27). However, this changed due to an unprecedented
outbreak that emerged in the temperate climate of Vancouver
Island (British Columbia, Canada) that subsequently expanded
farther into the Pacific Northwest (1, 8, 10, 16). Its sibling
species, Cryptococcus neoformans, differs ecologically and epi-
demiologically from C. gattii since it occurs on a global scale
and is linked with disease occurring in immunocompromised
individuals, such as HIV-positive patients and transplant pa-
tients who receive immune-suppressive medicines (7, 10, 18,
19, 31).
Cryptococcus gattii can be discerned from C. neoformans
using a wide range of microbiological and molecular tech-
niques (7, 20). A convenient method is the use of canavanine-
glycine-bromothymol blue (CGB) medium, which allows C.
gattii but not C. neoformans to grow and which changes the pH
indicator in the medium from green-yellowish to blue (18).
With the increasing use of molecular techniques, such as PCR
fingerprinting, restriction fragment length polymorphism
(RFLP) analysis of the PLB1 and URA5 loci, and amplified
fragment length polymorphism (AFLP) fingerprint analysis, as
well as several multilocus sequence typing (MLST) ap-
proaches, it became clear that C. gattii could be divided into
five distinct genotypes, named AFLP4/VGI, AFLP5/VGIII,
AFLP6/VGII, AFLP7/VGIV, and AFLP10 (the last one of
which is a recently observed novel genotype) (2, 6, 7, 13, 16, 20,
21, 23). Until recently, a serotype agglutination assay was
widely used to distinguish C. neoformans (serotypes A and D)
from C. gattii (serotypes B and C) (7, 27). In general, serotype
B strains are found in each of the five C. gattii AFLP genotypes,
but it seems that C. gattii serotype C strains are restricted to
genotypes AFLP5/VGIII and AFLP7/VGIV (2, 6, 16, 21, 27).
In addition, it was found that C. gattii and C. neoformans can
form interspecies hybrids, named genotype AFLP8 (C. neofor-
mans var. neoformans AFLP2/VNIII serotype D  C. gattii
AFLP4/VGI serotype B) and AFLP9 (C. neoformans var. grubii
AFLP1/VNI serotype A  C. gattii AFLP4/VGI serotype B).
These interspecies hybrids have, until now, been isolated only
from clinical samples, and they might have a higher virulence
potential than regular C. gattii or C. neoformans isolates (4, 5;
F. Hagen, K. Tintelnot, and T. Boekhout, unpublished data).
Treatment of cryptococcosis depends on, besides the im-
mune status of the patient, the severity and localization of the
infection (11). Severe cases of cryptococcosis in immunocom-
petent and -compromised patients are treated according to the
guidelines of the Infectious Diseases Society of America, ac-
cording to which treatment consists of an induction therapy for
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2 weeks with a combination of amphotericin B and flucytosine,
followed by a 10-week consolidation therapy with fluconazole
(11, 24).
Cryptococcus neoformans has been extensively studied for its
in vitro susceptibility to a wide variety of antifungal com-
pounds, including the new triazoles posaconazole, voricon-
azole, ravuconazole, and isavuconazole (12, 14, 28, 29, 33).
Despite the ongoing C. gattii outbreak, only a few studies using
relatively small sets of C. gattii isolates have been performed to
investigate their in vitro susceptibilities to amphotericin B,
flucytosine, fluconazole, and the new triazole antifungals (12,
15, 28–30). A few studies divided the C. gattii isolates into
groups according to their serotype or genotype (15, 29).
Therefore, we studied the in vitro susceptibilities of each of
the C. gattii genotypes from a large worldwide collection, sub-
divided by AFLP genotyping, to amphotericin B, flucytosine,
fluconazole, itraconazole, voriconazole, posaconazole, and the
new experimental broad-spectrum antifungal triazole isavu-
conazole.
MATERIALS AND METHODS
Strains and media. A worldwide collection of 350 C. gattii strains, represented
by 215 clinical isolates (61.4%), 57 veterinary isolates (16.3%), 73 environmental
isolates (20.9%), and 5 isolates from an unknown source (1.4%), were included
in this study. Strains were obtained from the public culture collections of the
CBS-KNAW Fungal Biodiversity Centre (Utrecht, Netherlands), BCCM-IHEM
Scientific Institute of Public Health (Brussels, Belgium), as well as the working
group collections of the authors. According to their geographical origins, the C.
gattii strains were grouped as being of African (n  28; 8.0%), Asian (n  22;
6.3%), Australian (n  20; 5.7%), European (n  101; 28.9%), North American
(n  95; 27.1%), South American (n  81; 23.1%), and unknown (n  3; 0.9%)
origin. The group of North American strains contained a set of 75 (24.1%) C.
gattii strains related to the ongoing Vancouver Island outbreak. The distributions
of the C. gattii strains, according to their geographical origins and sources of
isolation, are listed in Table 1. The strains were checked for purity and were
cultivated on malt extract agar medium (MEA; Oxoid, Basingstoke, United
Kingdom). After inoculation, the cultures were incubated for 2 days at 30°C. A
working collection was made by growing the C. gattii strains on MEA slants for
2 days at 30°C, after which the strains were stored at 4°C.
Genomic DNA extraction. An extraction procedure previously described by
Bolano et al. (3) was further optimized to obtain high-quality genomic DNA. C.
gattii strains were subcultured for 2 days at 30°C on yeast extract (1%)–peptone
(1%)–D-glucose (2%) agar supplemented with 0.5 M NaCl to prevent the for-
mation of a polysaccharide capsule. Approximately 150 l of C. gattii cells was
incubated for 3 h in 1.6 ml urea solution (10.7 M) at room temperature. After
centrifugation at 4,000 g for 2 min, the pellet was resuspended in 750 l of lysis
buffer (10% [wt/vol] sodium dodecyl sulfate, 10% [wt/vol] sodium Sarkosyl in TE
[Tris-EDTA] buffer, pH 8.0) and 750 l phenol-chloroform-isoamyl alcohol
(25:24:1, pH 8.0). The cells were disrupted by bead beating at full speed
(TissueLyser; Qiagen, Venlo, Netherlands) for 5 min. After centrifugation at
17,000  g for 15 min at 4°C, approximately 750 l supernatant was added to an
equal volume of ice-cold 96.2% ethanol and 100 l ice-cold 3.0 M sodium
acetate. Precipitation of genomic DNA was accelerated by incubating the solu-
tion at 20°C for 1 h. Genomic DNA was precipitated by centrifugation at
17,000  g for 15 min at 4°C, the pellet obtained was dissolved in 100 l
Tris-EDTA buffer (pH 8.0), and 1 l RNase (Invitrogen, Breda, Netherlands)
was added, followed by an incubation step at 37°C to degrade any remaining
RNA. The quality and quantity of genomic DNA were measured using an
ND-1000 spectrophotometer (Nanodrop, Wilmington, DE), and final working
solutions, each with a concentration of 100 ng/l, were prepared.
Mating typing, serotyping, and genotyping. The mating types of all isolates
were determined by partial amplification of the STE12 locus and either the
MATa or the MAT allele using two different primer sets, as described by Bovers
et al. (5). Briefly, 1 l genomic DNA (100 ng/l) was added to 24 l PCR mixture
consisting of 17.8 l double-distilled H2O, 0.75 l MgCl2 (50 mM; Bioline,
London, United Kingdom), 2.5 l 10 PCR buffer (Bioline), 1.9 l deoxynucleo-
side triphosphates (1 mM; Bioline), 0.1 l Taq DNA polymerase (5 U/l; Bio-
line), and 0.5 l of the forward and reverse primers (Biolegio, Nijmegen, Neth-
erlands) for either the STE12 allele (forward primer STE12-F809 [5-TTGA
CCTTTTRTTCCGCAATG-3] and reverse primer STE12-R1607 [5-TTTCT
TCTCCCCTGTTTATAGGC-3]) or the STE12a allele (forward primer
STE12a-F537 [5-GTTCTTTGGAATGGCTTATTTCATAT-3] and reverse
primer STE12a-R1299 [5-GMCTTGCGTGGATCATATCTA-3]). PCRs were
carried out with an initial denaturation step at 94°C for 5 min, followed by 35
cycles of denaturation at 94°C for 30 s, annealing at 58°C for 30 s, and extension
at 72°C for 1 min and then 72°C for 5 min. The reaction mixture was finally
cooled to 21°C. As a control, C. gattii mating type  strains CBS6956 and WM276
(CBS10510) and mating-type a strains CBS1930 and E566 (CBS11233) were
included.
A Cryptocheck agglutination test kit (Iatron Laboratories, Tokyo, Japan) was
used to determine the serotypes of those C. gattii isolates with contradictory
serotype data.
The genotype of each C. gattii isolate was determined using AFLP fingerprint
analysis, as described previously by Boekhout et al. (2). C. gattii isolates WM178
(CBS10082; AFLP6/VGII), A1M-R265 (CBS10514; AFLP6A/VGIIa), A1M-
R272 (CBS10865; AFLP6B/VGIIb), A6M-R38 (CBS11545; AFLP6C/VGIIc),
WM161 (CBS10081; AFLP5/VGIII), WM179 (CBS10078; AFLP4/VGI),
WM779 (CBS10101; AFLP7/VGIV), CBS10488 (AFLP8), CBS10496 (AFLP9),
and IHEM14941S (CBS11687; AFLP10) were used as controls to assign the
AFLP genotypes to all C. gattii isolates (2, 8, 13, 20, 21).
TABLE 1. Distribution of Cryptococcus gattii strains on the basis of AFLP genotype profiles, geographical origin,
and clinical, veterinary, or environmental source
AFLP
genotype
profile
No. (%) of strainsa
Geographical origin Source of isolation
Total
Africa Asia Australia Europe NorthAmerica
South
America Unknown Clinical Veterinary Environmental Unknown
AFLP4 16 (11.7) 14 (10.2) 8 (5.8) 74 (54.0) 9 (6.6) 15 (10.9) 1 (0.7) 76 (55.5) 29 (21.2) 30 (21.9) 2 (1.5) 137 (39.1)
AFLP5 1 (4.5) 2 (9.1) 10 (45.5) 7 (31.8) 2 (9.1) 15 (68.2) 5 (22.7) 2 (9.1) 22 (6.3)
AFLP6 3 (1.8) 6 (3.6) 11 (6.5) 19 (11.2) 75 (44.4) 55 (32.5) 103 (60.9) 27 (16.0) 38 (22.5) 1 (0.6) 169 (48.3)
AFLP6A 4 (5.5)* 1 (1.4)* 5 (6.8)* 56 (76.7)* 7 (9.6)* 36 (49.3)* 18 (24.7)* 18 (24.7)* 1 (1.4)* 73 (43.2)*
AFLP6B 3 (3.4)* 2 (2.3)* 10 (11.4)* 14 (15.9)* 11 (12.5)* 48 (54.5)* 61 (69.3)* 7 (8.0)* 20 (22.7)* 88 (52.1)*
AFLP6C 8 (100)* 6 (75.0)* 2 (25.0)* 8 (4.7)*
AFLP7 7 (63.6) 2 (18.2) 2 (18.2) 10 (90.9) 1 (9.1) 11 (3.1)
AFLP8 2 (33.3) 2 (33.3) 2 (33.3) 6 (100) 6 (1.7)
AFLP9 2 (66.7) 1 (33.3) 3 (100) 3 (0.9)
AFLP10 2 (100) 2 (100) 2 (0.6)
Total 28 (8.0) 22 (6.3) 20 (5.7) 101 (28.9) 95 (27.1) 81 (23.1) 3 (0.9) 215 (61.4) 73 (20.9) 57 (16.3) 5 (1.4) 350 (100)
a An asterisk indicates strains that belong to one of the subgenotypes within AFLP6, namely, AFLP6A, AFLP6B, or AFLP6C; these strains are the cumulative
number of strains in the main genotype AFLP6 group.
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In vitro susceptibility testing. The MICs of amphotericin B (Bristol Myers
Squibb, Woerden, Netherlands), flucytosine (Valeant Pharmaceuticals, Zoeter-
meer, Netherlands), fluconazole and voriconazole (Pfizer Central Research,
Sandwich, Kent, United Kingdom), itraconazole (Janssen Cilag, Tilburg, Neth-
erlands), posaconazole (Schering-Plough Corp., Kenilworth, NJ), and isavucon-
azole (Basilea Pharmaceutica, Basel, Switzerland) were determined using the
broth microdilution method, in accordance with the guidelines in CLSI docu-
ment M27-A3 (9). Drug-free and sterile controls were included. Paecilomyces
variotii (ATCC 22319) and Candida krusei (ATCC 6258, CBS573) were used for
quality control. The microtiter plates were incubated for 72 h at 35°C under
aerobic conditions.
Data analysis. Values for the MIC50 and MIC90 were obtained by ordering the
MIC data for each antifungal in ascending arrays and selecting the median and
90th quantile, respectively, of the MIC distribution. Geometric mean MICs were
computed using Microsoft Office Excel 2007 software, for which purpose values
of x were set equal to 0.5x and values more than y were set equal to 2y (x and
y are the lowest and highest MICs, respectively, in the range). A two-tailed
Mann-Whitney-Wilcoxon test was applied to compare the MIC values between
different C. gattii genotypes; and a multivariate analysis of variance (MANOVA)
test was applied to compare geographical origins, AFLP genotype profiles, and
MIC values (StatistiXL software, version 1.8, StatistiXL, Nedland, WA, Austra-
lia). A P value of 0.05 was considered statistically significant.
RESULTS
Mating typing, serotyping, and genotyping. On the basis of
the AFLP genotypes, the 350 C. gattii isolates were divided
into five haploid AFLP genotypes (n  341; 97.4%) and two
hybrid AFLP genotypes (n  9; 2.6%), namely, AFLP4 (n 
137; 39.1%), AFLP5 (n  22; 6.3%), AFLP6 (n  169;
48.3%), AFLP7 (n  11; 3.1%), AFLP8 (n  6; 1.7%),
AFLP9 (n  3; 0.9%), and AFLP10 (n  2; 0.6%). The
majority of the 215 clinical C. gattii isolates belonged to
either genotype AFLP4 (n  76; 35.4%) or genotype AFLP6
(n  103; 47.9%). Strains that clustered within genotype
AFLP6 could be further divided into the three subgenotypes
AFLP6A (n  73; 43.2%), AFLP6B (n  88; 52.1%),
and AFLP6C (n  8; 4.7%) (Table 1).
The serotypes of the genotype AFLP7 strains were investi-
gated in more detail, since several of these isolates were, ac-
cording to the literature, known to be serotypes B and C (6, 21,
23). However, we determined that all C. gattii AFLP7 isolates
were serotype C. The two genotype AFLP10 strains were de-
termined to be serotype B. Within the other AFLP genotypes,
no contradictions from the literature were found, and serotyp-
ing was omitted for these groups.
The mating types for all C. gattii isolates were determined by
amplification of either the STE12a or the STE12 allele. This
revealed that within the group of 341 haploid C. gattii strains
(genotypes AFLP4 to AFLP7 and AFLP10), the mating type 
strains (n  296; 86.8%) were dominant over the mating type
a strains (n  45; 13.2%).
In vitro susceptibility testing. MIC ranges, MIC50s, geomet-
ric mean MICs, and MIC90s related to AFLP genotype are
presented in Table 2. For each antifungal for each AFLP
genotype examined, the MIC50 and geometric mean MIC val-
ues differed by1 log2 dilution step, indicating that in all cases
the MIC50s obtained by inspection reasonably reflect the cen-
tral tendency of antifungal susceptibility of the population.
Isavuconazole had the lowest MIC90s for all C. gattii iso-
lates surveyed by at least 1 log2 dilution step. The overall
ranges of MICs for each of the seven drugs were 0.016 to
1 g/ml for amphotericin B, 0.125 to 64 g/ml for flucy-
tosine, 0.25 to 64 g/ml for fluconazole, 0.016 to 1 g/ml
for itraconazole and voriconazole, and  0.016 to 0.5 g/ml
for posaconazole and isavuconazole. The geometric mean
MIC values varied widely when they were calculated for all
350 C. gattii strains (Table 2). The highest geometric mean
MIC was 3.573 g/ml for fluconazole, followed by geometric
mean MICs of 2.896 g/ml for flucytosine and 0.272 g/ml
for amphotericin B and much lower geometric mean MICs
for itraconazole and the new triazoles voriconazole,
posaconazole, and isavuconazole (0.124, 0.108, 0.113, and
0.051 g/ml, respectively).
Comparison of geometric mean MIC values of the C. gattii
strains obtained from clinical, environmental, and veteri-
nary sources revealed that the last category of strains had
decreased susceptibility to all seven antifungal drugs investigated
except flucytosine in comparison to the susceptibilities of the
clinical and environmental strains. When the susceptibilities of
the clinical versus veterinary C. gattii strains and the environmen-
tal versus veterinary C. gattii strains were compared, these differ-
ences were significant for itraconazole (P  0.026 and P  0.02,
respectively) and the novel triazoles posaconazole (P 0.008 and
P  0.02, respectively), voriconazole (P  0.013 and P  0.008,
respectively), and isavuconazole (P  0.004 and P  0.002, re-
spectively).
A MANOVA showed that there was a significant difference
(P  0.001) between the susceptibility values obtained for the
seven antifungal compounds and the geographical origins of
the C. gattii strains (Table 3). It was observed that the MIC
values of amphotericin B and flucytosine contributed to this
significant difference (P  0.003 and P  0.02, respectively).
This difference was caused by C. gattii strains from Europe,
which differed significantly in their susceptibility to amphoter-
icin B compared to the susceptibilities of strains from Africa
(P  0.002), Asia (P  0.014), Australia (P  0.041), North
America (P  0.001), and South America (P  0.019), which
were found to be less susceptible. For flucytosine, North Amer-
ican C. gattii strains had a significantly higher geometric mean
MIC than African (P  0.001), Asian, (P  0.001), European
(P 0.001), and South American (P 0.001) strains (Table 3).
When all C. gattii genotype AFLP4 and AFLP6 strains (Table
2) were analyzed by MANOVA, it was observed that it was not
the geographical origin but the genotype that contributed to
the significant differences in antifungal susceptibility patterns
(P  0.001). The antifungal drugs amphotericin B (P  0.001),
fluconazole (P  0.001), itraconazole (P  0.038), voricon-
azole (P  0.001), and isavuconazole (P  0.001) were found
to be highly significant contributors to this phenotypic differ-
ence between AFLP4 and AFLP6 C. gattii strains.
Clinical strains that belonged to the genotype AFLP6 cluster
had a significantly (P 0.05) higher geometric mean MIC than
strains of genotype AFLP4 for six of the seven antifungal
compounds tested. However, both genotypes had almost iden-
tical geometric mean MICs for posaconazole (0.112 and 0.124
g/ml, respectively; P  0.391). Strikingly, clinical AFLP6 iso-
lates had high geometric mean MICs of 4.961 and 5.638 g/ml
for flucytosine and fluconazole, respectively, compared to
those for clinical isolates within genotype AFLP4 (1.401 and
2.467 g/ml, respectively).
C. gattii strains within the Vancouver outbreak-related ge-
notype, genotype AFLP6, were divided into the three defined
subgenotypes AFLP6A (n  73; 43.2%), AFLP6B (n  88;
VOL. 54, 2010 AFLP TYPING AND SUSCEPTIBILITY TESTING OF C. GATTII 5141
 o
n
 M
ay 1, 2017 by RADBO
UD UNIVERSITEIT NIJM
EG
EN
http://aac.asm
.org/
D
ow
nloaded from
 
TABLE 2. MIC ranges, MIC50s, MIC90s, and geometric mean MICs for all 350 C. gattii strains and AFLP genotypes
Strain Drug
MIC (g/ml)
Range 50% Geometric mean 90%
All C. gattii strains (n  350) Amphotericin B 0.016–1 0.25 0.272 0.5
Flucytosine 0.125–64 2 2.896 8
Fluconazole 0.25–64 4 3.573 8
Itraconazole 0.016–1 0.125 0.124 0.25
Voriconazole 0.016–1 0.125 0.108 0.25
Posaconazole 0.016–0.5 0.125 0.113 0.25
Isavuconazole 0.016–0.5 0.063 0.051 0.125
C. gattii AFLP4 (n  137) Amphotericin B 0.016–0.5 0.25 0.238 0.5
Flucytosine 0.125–16 1 1.667 4
Fluconazole 0.25–16 2 2.550 8
Itraconazole 0.016–0.5 0.125 0.119 0.25
Voriconazole 0.016–0.25 0.063 0.090 0.25
Posaconazole 0.016–0.5 0.125 0.123 0.25
Isavuconazole 0.016–0.5 0.031 0.044 0.125
C. gattii AFLP5 (n  22) Amphotericin B 0.125–0.5 0.25 0.214 0.5
Flucytosine 0.5–4 2 1.938 4
Fluconazole 0.25–8 2 2.064 4
Itraconazole 0.016–0.25 0.063 0.078 0.125
Voriconazole 0.016–0.125 0.063 0.059 0.125
Posaconazole 0.031–0.25 0.063 0.076 0.125
Isavuconazole 0.016–0.063 0.031 0.023 0.063
C. gattii AFLP6 (n  169) Amphotericin B 0.125–1 0.25 0.312 0.5
Flucytosine 0.5–64 4 5.033 8
Fluconazole 0.5–64 4 5.137 16
Itraconazole 0.016–1 0.125 0.148 0.5
Voriconazole 0.016–1 0.125 0.142 0.25
Posaconazole 0.016–0.5 0.125 0.119 0.25
Isavuconazole 0.016–0.5 0.063 0.067 0.25
C. gattii AFLP6A (n  73) Amphotericin B 0.125–0.5 0.25 0.299 0.5
Flucytosine 1–16 4 5.268 8
Fluconazole 0.5–32 4 4.235 8
Itraconazole 0.016–1 0.125 0.123 0.5
Voriconazole 0.016–1 0.125 0.117 0.25
Posaconazole 0.016–0.5 0.125 0.105 0.25
Isavuconazole 0.016–0.5 0.063 0.050 0.25
C. gattii AFLP6B (n  88) Amphotericin B 0.125–1 0.25 0.319 0.5
Flucytosine 0.5–64 4 4.609 8
Fluconazole 1–16 8 5.438 16
Itraconazole 0.016–0.5 0.25 0.162 0.25
Voriconazole 0.016–0.5 0.125 0.152 0.25
Posaconazole 0.016–0.25 0.125 0.124 0.25
Isavuconazole 0.016–0.25 0.063 0.078 0.25
C. gattii AFLP6C (n  8) Amphotericin B 0.25–0.5 0.25 0.354 0.5
Flucytosine 4–16 8 8.724 16
Fluconazole 8–64 16 16.000 64
Itraconazole 0.25–0.5 0.25 0.297 0.5
Voriconazole 0.25–1 0.25 0.354 1
Posaconazole 0.125–0.5 0.25 0.229 0.5
Isavuconazole 0.063–0.5 0.25 0.193 0.5
C. gattii AFLP7 (n  11) Amphotericin B 0.125–0.5 0.5 0.343 0.5
Flucytosine 1–8 2 2.269 8
Fluconazole 0.5–32 4 4.537 16
Itraconazole 0.016–0.25 0.125 0.104 0.25
Voriconazole 0.031–0.25 0.125 0.117 0.25
Posaconazole 0.031–0.25 0.125 0.110 0.25
Isavuconazole 0.016–0.25 0.063 0.052 0.125
C. gattii AFLP8–10 (n  11) Amphotericin B 0.125–0.5 0.25 0.220 0.25
Flucytosine 1–8 1 1.656 8
Fluconazole 0.5–8 2 2.130 8
Itraconazole 0.016–0.125 0.063 0.043 0.125
Voriconazole 0.016–0.25 0.031 0.059 0.125
Posaconazole 0.016–0.125 0.063 0.043 0.125
Isavuconazole 0.016–0.063 0.016 0.020 0.063
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52.1%), and AFLP6C (n  8; 4.7%). Significant differences in
the geometric mean MICs between C. gattii AFLP6A and
AFLP6B strains were found for all antifungal drugs except
amphotericin B (P  0.398) and flucytosine (P  0.091); how-
ever, the geometric mean MICs were within 1 log2 dilution
step. There was also no significant difference in amphotericin B
MICs when AFLP6A and AFLP6C strains (P  0.353) and
AFLP6B and AFLP6C strains (P  0.607) were compared,
while all other antifungal compounds tested showed significant
differences between these subgenotypes (Table 2). However,
the number of strains within subgenotype AFLP6C is too small
to compare its antifungal susceptibility characteristics with
those of the larger group of strains within genotypes AFLP6A
and AFLP6B.
DISCUSSION
Despite the fact that C. gattii has become an important
primary pathogen due to the expanding outbreak in British
Columbia (Canada) and the Pacific Northwest (United States),
there is a lack of in-depth studies on the susceptibilities of large
sets of C. gattii strains to conventional and new antifungal
compounds (10). In particular, the relation between suscepti-
bility profiles and the different genotypes within the C. gattii
complex has rarely been studied and has been studied with only
low numbers of isolates (15). In this study, we have compared
the susceptibilities of 350 C. gattii isolates collected from dif-
ferent geographical regions and sources (e.g., clinical, veteri-
nary, and environmental) to four clinically used antifungal
TABLE 3. In vitro susceptibilities of the C. gattii strains according to geographical origin
C. gattii strain origin Drug
MIC (g/ml)
Range 50% Geometric mean 90%
Africa (n  28) Amphotericin B 0.125–0.5 0.25 0.320 0.5
Flucytosine 1–16 2 2.378 8
Fluconazole 0.25–32 4 4.308 8
Itraconazole 0.016–0.25 0.125 0.111 0.25
Voriconazole 0.016–0.25 0.125 0.114 0.25
Posaconazole 0.016–0.25 0.125 0.122 0.25
Isavuconazole 0.016–0.5 0.063 0.058 0.125
Asia (n  22) Amphotericin B 0.125–0.5 0.25 0.312 0.5
Flucytosine 0.5–16 2 2 8
Fluconazole 0.5–16 2 2.741 8
Itraconazole 0.031–0.5 0.125 0.1 0.250
Voriconazole 0.031–0.25 0.063 0.08 0.250
Posaconazole 0.063–0.5 0.125 0.107 0.250
Isavuconazole 0.016–0.25 0.031 0.044 0.125
Australia (n  20) Amphotericin B 0.125–0.5 0.25 0.297 0.5
Flucytosine 1–32 2 3.138 16
Fluconazole 0.5–16 2 2.639 8
Itraconazole 0.063–0.5 0.125 0.134 0.25
Voriconazole 0.031–0.25 0.125 0.091 0.25
Posaconazole 0.031–0.5 0.125 0.121 0.25
Isavuconazole 0.016–0.125 0.063 0.049 0.125
Europe (n  101) Amphotericin B 0.016–1 0.25 0.223 0.5
Flucytosine 0.125–64 2 2.263 8
Fluconazole 0.5–32 4 3.301 8
Itraconazole 0.016–0.5 0.125 0.137 0.25
Voriconazole 0.016–1 0.125 0.112 0.25
Posaconazole 0.016–0.5 0.125 0.131 0.25
Isavuconazole 0.016–0.5 0.063 0.055 0.125
North America (n  95) Amphotericin B 0.125–0.5 0.25 0.300 0.5
Flucytosine 1–16 4 4.334 8
Fluconazole 0.5–64 4 4.240 8
Itraconazole 0.016–1 0.125 0.121 0.25
Voriconazole 0.016–1 0.125 0.114 0.25
Posaconazole 0.016–0.5 0.125 0.103 0.25
Isavuconazole 0.016–0.5 0.063 0.047 0.25
South America (n  81) Amphotericin B 0.125–1 0.25 0.277 0.5
Flucytosine 0.5–16 4 2.865 8
Fluconazole 0.25–16 4 3.548 16
Itraconazole 0.016–1 0.125 0.126 0.25
Voriconazole 0.016–0.5 0.125 0.111 0.25
Posaconazole 0.016–0.5 0.125 0.104 0.25
Isavuconazole 0.016–0.5 0.063 0.051 0.25
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compounds, i.e., amphotericin B, flucytosine, fluconazole, and
itraconazole, and the three novel triazoles voriconazole,
posaconazole, and isavuconazole. The older antifungal drugs,
amphotericin B, flucytosine, and fluconazole, had lower levels
of activity against all C. gattii isolates than itraconazole and the
novel triazoles, as visualized by their geometric mean MIC
values (Table 2). The observation that flucytosine and flucon-
azole had poorer antifungal activity against C. gattii, as well as
against its sibling, C. neoformans, was a consistent finding in
previous studies (12, 14, 15, 25, 29, 30). For testing of C.
neoformans susceptibility to amphotericin B, flucytosine, and
fluconazole, so-called surrogate breakpoints were introduced
by Pfaller et al. (25). C. neoformans was regarded to be highly
susceptible to amphotericin B when the MIC in vitro was 1
g/ml. In this study, none of the 350 C. gattii strains showed
higher in vitro MICs, and thus, all isolates remained highly
susceptible. Similar findings were reported in three other stud-
ies, which tested lower numbers of isolates (15, 29, 30). On the
contrary, decreased in vitro susceptibility (16 g/ml) to flu-
conazole was observed for 26 strains (7.4%), and only one
clinical isolate within the AFLP6C cluster appeared to have
high-level resistance (MICs,64 g/ml) to fluconazole in vitro.
With respect to flucytosine, the number of strains within the
group of isolates with decreased susceptibility (MICs, 8 g/
ml) was 84 (24.3%), of which 9 (2.57%) belong to the category
of high-level-resistant isolates (MICs, 32 g/ml).
The majority of C. gattii isolates in the present study belong
to either genotype AFLP4 (n  137; 39.1%) or AFLP6 (n 
169; 48.3%), while the remaining 44 (12.6%) C. gattii isolates
belong to one of the minor genotypes (AFLP5 or AFLP7 to
AFLP10) that are more restricted to certain geographical re-
gions and which less frequently cause infections (7, 27). The
preponderance toward C. gattii strains with an AFLP4 or
AFLP6 genotype can be interpreted as being the result of the
analysis of a nonrepresentative selection of strains. This ap-
parent overrepresentation might be due to the inclusion of
preserved culture collection strains from well-studied geo-
graphical localities, such as Australia and the C. gattii outbreak
region in North America (27). These localities were repeatedly
found to harbor more genotype AFLP4 or AFLP6 strains
rather than strains of genotype AFLP5 or AFLP7 (15, 16, 27).
The South American continent has been shown to be a melting
pot of known haploid AFLP genotypes compared to the diver-
sity of genotypes in other localities (21, 23, 27). However,
preserved C. gattii strains from the less well studied regions,
Africa, Asia, and Europe, were found to follow the trend that
strains with an AFLP4 genotype profile were more frequently
isolated than others (13, 27). Hence, it appears that C. gattii
AFLP4 and AFLP6 strains are collected and preserved more
frequently and that the availability and exchangeability of
strains can influence studies toward a specific genotype (13,
27). It might influence the outcome of susceptibility values
when only the geographical origin is taken into consideration,
while a combined analysis of the geographical origin with a
genotyping method (e.g., RFLP, AFLP, or MLST) will reveal
more subtle differences, as has been shown in the current
study.
When only the clinical C. gattii strains from the two major
genotypes, genotypes AFLP4 and AFLP6, were compared, it
appeared that strains belonging to AFLP6 (n  103) had
significantly (P  0.05) higher geometric mean MICs for six of
the antifungal compounds tested than strains belonging to ge-
notype AFLP4 (n  76). However, both genotypes had almost
identical geometric mean MICs for posaconazole (0.112 and
0.124 g/ml, respectively). Strikingly, clinical AFLP6 isolates
had higher geometric mean MICs of 4.961 and 5.638 g/ml for
flucytosine and fluconazole, respectively, than clinical isolates
within genotype AFLP4 (1.401 and 2.467 g/ml, respectively).
Similar results were recently reported for a collection of 43
North American C. gattii isolates (15). In the current study,
fluconazole and flucytosine had the lowest levels of activity
against the C. gattii strains. Itraconazole, which has been used
clinically to treat cryptococcosis, had a MIC90 of only 0.25
g/ml, which is 1 or 2 log2 dilutions lower than the MIC90s
previously found by others (15, 30). Isavuconazole, posacon-
azole, and voriconazole demonstrated excellent potency
against each isolate and all AFLP genotypes, including isolates
with reduced fluconazole susceptibilities.
The results for voriconazole (MIC90, 0.25 g/ml) were com-
parable to those of other studies (15, 29, 30) and 1 log2 dilution
higher than that found in one study (22). Posaconazole MICs
differed by a maximum of 2 log2 dilution steps between this and
previous studies. Isavuconazole had the lowest MIC90 (0.125
g/ml) in this large study, and the MIC90 was within 1 log2
dilution of that recently reported (MIC90, 0.063 g/ml) by
Thompson et al. (29). When isolates were tested by Etest,
these authors also found a MIC90 of 0.125 g/ml (28). Isavu-
conazole has even better in vitro activity against C. neoformans,
a finding which also holds true for the other antifungal com-
pounds (14).
All antifungal compounds tested were active against all C.
gattii genotypes; however, some strains showed high MICs, as
was the case for amphotericin B (up to 1 g/ml), flucytosine
(64 g/ml), fluconazole (64 g/ml), and itraconazole and
voriconazole (1 g/ml). The two novel triazoles isavuconazole
and posaconazole had relatively low MIC values compared to
those of the other antifungal compounds tested. We conclude
that amphotericin B, itraconazole, voriconazole, posaconazole,
and isavuconazole were the drugs that were the most active
against C. gattii isolates in vitro. Isavuconazole, with its attrac-
tive pharmacological and toxicological properties and avail-
ability in oral and parenteral formulations, may be a welcome
addition to the clinician’s antifungal armamentarium to fight
this pathogen.
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